Recent Court Rulings and Obviousness-Type Double Patenting Impact

Patent lawyers love a tidy rule almost as much as inventors love a broad claim. Obviousness-type double patenting, or OTDP, is not tidy. It is a judge-made doctrine built to stop patentees from stretching exclusivity by claiming obvious variations of the same invention in separate patents. For years, many companies treated OTDP as a manageable nuisance. File a terminal disclaimer, keep moving, and pretend your portfolio is perfectly groomed. Recent rulings have wrecked that casual attitude.

The big change is not that OTDP suddenly exists. It is that courts and the USPTO have been sharpening the doctrine’s edges. In re Cellect turned patent term adjustment into a real OTDP risk. Allergan v. MSN then pulled back, at least for a specific parent-child patent scenario. The Federal Circuit’s January 2025 Regeneron decisions reminded everyone that OTDP still turns on claim-by-claim patentable distinctness, not hand-waving and vibes. And now the USPTO is actively revisiting the question of what counts as a proper OTDP reference in Ex parte Baurin. In other words, the doctrine is no longer sleepy. It is caffeinated, argumentative, and very interested in your patent family tree.

Why OTDP matters more than ever

At its core, OTDP tries to prevent an unjustified timewise extension of patent rights. The classic problem is simple: one inventor or one owner should not get one patent, then a second patent on a not-really-different version, and use the second patent to push exclusivity farther into the future. That policy sounds straightforward until patent terms stop lining up neatly.

Modern patent portfolios are full of continuations, different prosecution timelines, patent term adjustment for USPTO delay, and patent term extension for regulatory delay. Those moving parts create expiration dates that do not always match filing dates or issuance dates. That is where the recent rulings have had their biggest impact. The courts have made clear that expiration mechanics matter, but not always in the same way, and not always for the same reason.

Terminal disclaimers are not magic wands

A terminal disclaimer can still solve many OTDP problems during prosecution, but it is not a superhero cape. It shortens the later patent’s term and generally requires common ownership for enforceability. It also becomes useless if filed too late, particularly after the reference patent has expired. That means the once-routine “we will fix it later” approach now carries more risk than many patent owners would like to admit. In patent practice, “later” has a nasty habit of showing up dressed as “too late.”

The ruling that changed the mood: In re Cellect

The Federal Circuit’s 2023 decision in In re Cellect remains the earthquake beneath today’s OTDP landscape. The patents at issue shared priority, but some received PTA and therefore expired later than a related family patent that had not received the same adjustment. Cellect argued that PTA should be treated like patent term extension, meaning OTDP should be evaluated without counting the added term. The court rejected that argument.

That holding mattered because the Federal Circuit said OTDP for a patent that received PTA is measured using the expiration date after PTA has been added. That is a brutal sentence for anyone who assumed congressionally granted PTA would stay comfortably insulated from a judge-made doctrine. The court drew a sharp distinction between PTA and PTE. PTA addresses prosecution delay at the USPTO for a particular patent. PTE, by contrast, addresses regulatory delay and serves a different statutory purpose. So, according to Cellect, PTA can expose a patent to OTDP in a way that PTE does not.

The practical fallout was immediate. Patent owners began rechecking families that once looked harmless. Continuations that issued later but expired earlier suddenly became dangerous references. Earlier-filed patents that received PTA no longer felt like gifts from Congress. They felt more like gifts with a hidden invoice.

The Supreme Court did not rescue patentees

Plenty of patent owners hoped the Supreme Court would step in and soften Cellect. That did not happen. Certiorari was denied in October 2024, leaving the Federal Circuit’s framework in place. For portfolio managers, that meant Cellect was not a passing storm. It was the weather.

Allergan v. MSN: the important limit on Cellect

If Cellect made patent owners sweat, Allergan v. MSN gave them a towel. In August 2024, the Federal Circuit confronted a different question: can a first-filed, first-issued, later-expiring parent claim be invalidated by a later-filed, later-issued, earlier-expiring child claim that shares the same priority date? The court said no.

That distinction is huge. The Federal Circuit explained that the first-filed, first-issued patent in the family sets the maximum period of exclusivity for the claimed subject matter and patentably indistinct variants in that particular setup. In other words, the parent that came first and issued first does not become invalid merely because a later child patent expired sooner. The child is not extending the parent’s exclusivity; if anything, it is the shorter-lived sibling at the reunion.

Allergan did not overrule Cellect. It limited how far people could push it. The court emphasized that Cellect answered the PTA question, not every possible question about what qualifies as a proper OTDP reference. That nuance matters. Patent law often changes less through dramatic reversals than through careful, surgical narrowing. One case opens the door, the next case tells everyone not to lean on the hinges.

What Allergan means in real life

For companies with classic parent-child continuation strategies, Allergan is a genuine comfort. A foundational parent patent that was filed first, issued first, and picked up PTA is not automatically doomed just because later continuations in the same family expired earlier. But the comfort is not universal. The facts matter. The order of filing matters. The order of issuance matters. The relationship between the patents matters. And if your portfolio facts drift away from Allergan, your sense of safety should probably drift with them.

January 2025: Regeneron shows OTDP is still a claim-by-claim fight

The Federal Circuit’s January 2025 Regeneron decisions did something useful: they reminded everyone that OTDP is not just about patent terms and family charts. It is also, and very much, about whether claims are actually patentably distinct.

In the Regeneron appeals, the court concluded that particular claim differences, including a specific 98% stability requirement and glycosylation, were enough to render the later claims patentably distinct over the reference claims. That matters because some OTDP arguments are presented as if once two patents live in the same family and one expires later, the later patent is basically guilty until proven innocent. The Regeneron rulings pushed back on that lazy thinking.

Patentable distinctness still demands disciplined analysis. Courts must look at the claim differences and ask whether those differences would have been obvious, with the relevant factual inquiries in mind. A reference claim that is broader is not automatically fatal. A shared specification is not automatically fatal. And simply pointing at an example in the patent and yelling “Aha!” is not the same as proving the claims are not distinct. Sometimes the details do save the day, which is comforting for innovators and very annoying for shortcutters.

The USPTO wildcard: Ex parte Baurin and the Appeals Review Panel

Just when practitioners thought they had enough OTDP excitement, the USPTO added another plot twist. In Ex parte Baurin, the PTAB reversed OTDP rejections based on later-filed, later-expiring references. That decision was notable because it treated those references as improper for OTDP in that posture. Then, in March 2026, the USPTO convened an Appeals Review Panel to reconsider the issue and invited amicus briefing through March 27, 2026.

The message is clear: the agency knows the law is unsettled at the edges. That does not mean applicants can rely on Baurin as settled law. They cannot. The decision is not the final word, and the USPTO is openly reconsidering the underlying questions. But it does show that reference-patent selection remains one of the hottest OTDP battlegrounds right now.

Why Baurin matters even before a final answer

Baurin matters because it exposes a basic tension in OTDP doctrine. Is the doctrine mainly about preventing unjustified term extension? Is it also about avoiding harassment by multiple owners asserting not-distinct rights? How should examiners handle projected expiration dates during prosecution? Those are not academic questions. They affect whether examiners can rely on certain references, whether applicants must disclaim term, and whether portfolio design needs to change at the drafting stage instead of during cleanup after issuance.

The business impact of recent OTDP rulings

1. Patent family audits are now mandatory, not optional

After Cellect, companies should be auditing related patents for mismatched expiration dates, especially where PTA is involved. If a family has multiple continuations, divisionals, or continuation-in-part strategies, simply assuming the earliest filing date tells the whole story is risky. It does not. You need a map of actual expiration dates, disclaimers, ownership, and prosecution history. Patent families now need less genealogy hobby energy and more forensic accounting energy.

2. Continuation strategy needs tighter discipline

Allergan helped parents in one specific posture, but it also highlighted how much the continuation sequence matters. Prosecutors should think more carefully about which claims belong in the first-filed application, what inventions are valuable enough to protect early, and whether later continuations are creating unintended OTDP exposure. The old strategy of “file the continuation and we will sort out term issues later” is looking a little like building a porch and promising to measure the door afterward.

3. Different ownership structures can create nasty surprises

One of the more underappreciated risks is ownership fragmentation. In some cases, the USPTO can issue an OTDP rejection over a reference patent or application tied to a different ownership entity, but a terminal disclaimer may not be available to solve the problem. That turns a routine prosecution issue into something much more painful. Joint ventures, spinouts, university-company collaborations, and complex corporate families should pay very close attention here. OTDP does not care whether your org chart looks elegant in PowerPoint.

4. Litigators now have better pressure points

For challengers, recent OTDP law has created sharper tools. PTA is now an attack surface. Continuation chains can be mined for reference patents. Late-filed terminal disclaimers may be unavailable. On the flip side, patentees have better arguments too, especially under Allergan and the recent Regeneron rulings, where reference selection and actual claim distinctness can defeat overbroad OTDP attacks. The doctrine is more dangerous, but it is also more fact-sensitive. That is good for lawyers who like nuance and bad for anyone who wanted a one-sentence answer.

What smart patent owners should do next

Recalculate every expiration date that matters

Do not rely on family relationships alone. Calculate actual expiration dates, including PTA, PTE, and any terminal disclaimers already on file. OTDP lives in the gaps between those dates.

Review parent-child structures before filing new continuations

Think prospectively. If the parent is likely to accrue substantial PTA, ask how later-filed child applications may look under Allergan, and how a challenger might try to distinguish your facts from that case.

Do not treat terminal disclaimers as reflexes

A terminal disclaimer can fix one problem while creating another by sacrificing valuable term. It should be a strategic choice, not an autopilot move made on a sleepy Friday afternoon.

Stress-test distinctness, not just ownership

Regeneron is a good reminder that claim differences matter. If you are drafting follow-on claims, build a record that supports real distinctness. Explain why the later claim is not just a dressed-up version of the earlier one.

Conclusion

Recent court rulings have transformed OTDP from a doctrine many portfolio teams treated as a technical afterthought into a front-line strategic issue. In re Cellect made PTA count in a way many patentees did not expect. Allergan v. MSN created an important limit by protecting the first-filed, first-issued parent in a specific continuation setting. The Regeneron rulings showed that patentable distinctness still has real teeth. And the USPTO’s ongoing review in Ex parte Baurin suggests the law around proper OTDP references is still evolving.

The broader lesson is simple. Patent term is no longer just a calendar problem. It is a litigation problem, a prosecution problem, a drafting problem, and occasionally a corporate-structure problem wearing a fake mustache. Companies that want strong portfolios should stop viewing OTDP as a late-stage cleanup task. In the current environment, OTDP has become part of core patent strategy from the first filing onward.

Real-World Experience: What This Topic Looks Like in Practice

In practice, the impact of these rulings usually shows up long before anyone files a brief citing Cellect or Allergan. It starts in portfolio meetings. Someone puts a family chart on the screen. At first, the room feels calm. There is a parent case, a few continuations, maybe a divisional or two, and everyone assumes the structure is ordinary. Then someone adds the actual expiration dates, including PTA, and the room suddenly gets quieter. The patents that seemed neatly aligned are no longer aligned at all. A continuation filed years later may expire earlier. A parent that seemed untouchable may now be vulnerable unless its facts fit squarely within Allergan. What looked like a clean family starts to resemble a bowl of legal spaghetti.

Prosecutors are feeling the change too. Before Cellect, there was often a practical instinct to focus on allowance first and sort out term issues if they became urgent later. Now that approach feels much riskier. A prosecutor drafting continuation claims may need to think not only about novelty and nonobviousness over third-party prior art, but also about how a future challenger could compare the new claims to earlier family claims. That changes drafting behavior. The best practitioners are now building clearer explanations for why follow-on claims are materially different, technically meaningful, and not just cosmetic edits in a more expensive suit.

Litigators, meanwhile, are using OTDP more creatively. A patent that once looked strong because it had years of PTA may now attract extra scrutiny instead of admiration. Defendants can ask whether the additional term created a later expiration date over a not-patentably-distinct reference. They can examine terminal disclaimers, prosecution timing, ownership history, and family structure with fresh intensity. On the patentee side, lawyers are responding by leaning harder into the specific facts that matter after Allergan: which patent was filed first, which issued first, which actually set the family’s maximum exclusivity, and whether the asserted claims are genuinely distinct under the careful analysis reinforced by Regeneron.

Business teams feel the effects as well. Licensing negotiations can shift when a supposedly long-lived patent is exposed to OTDP risk. Due diligence for acquisitions has become more exacting. Buyers do not just ask, “How many patents are in the family?” They ask, “Which one expires first, why, and what happens if a court compares these claims?” That is a more sophisticated conversation, but also a more demanding one. Patent value is not just about having a stack of assets. It is about understanding which assets can survive contact with current OTDP doctrine.

The practical lesson from all of this is not panic. It is preparation. The companies handling this issue best are the ones that audit early, draft carefully, and treat OTDP as a strategic design constraint rather than an annoying procedural footnote. In the current legal climate, that mindset is no longer optional. It is the difference between owning a well-managed patent estate and discovering, far too late, that one of your strongest-looking patents was standing on a trap door the whole time.